Home › NCT07433621
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
A Pilot Study to Evaluate Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Who can join
Ages 2 and older · Men
Full eligibility criteria
Inclusion Criteria: * Male patients * Diagnosis of XIAP deficiency * Patients ≥2 years of age * Serum IL-18 ≥600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL) * Able to take enteral medication Exclusion Criteria: * Renal failure requiring dialysis * Total bilirubin \>3 mg/dl and/or SGPT \>300 at time of enrollment * Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons * Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons * Patients who are at risk of pregnancy or fathering a child and are unable to use acceptable methods of birth control during the length of the study * Patients who have received quercetin or any over the counter anti-oxidant supplementation within last 1 month * Patients with unstable disease status or other medical issues requiring hospitalization or rapid escalation of medical care * Participating in another therapeutic study for XIAP deficiency
About the study
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
What is being tested
- Quercetin (drug)
Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 12 · Started: Feb 26, 2026
Contact the study team
- Kelly McIntosh · Phone: 513-803-0460
- Richard Cooper · Phone: 513-803-7450
Official record on ClinicalTrials.gov — NCT07433621
Locations in the U.S.
| Ohio | Cincinnati Children's Hospital Medical Center, Cincinnati |
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.